

Thyquidity™ (levothyroxine sodium) – New drug approval

- On November 30, 2020, the [FDA approved](#) Regulance/Vertice Specialty Group's [Thyquidity \(levothyroxine sodium\)](#), for:
 - Replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism
 - Adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
- Limitations of use for Thyquidity include:
 - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Thyquidity may induce hyperthyroidism
 - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
- Levothyroxine sodium is already available in several other formulations, including generic [tablets](#). In addition, another brand oral solution formulation, [Tirosint®-SOL](#), is available.
 - Tirosint-SOL and generic tablets of levothyroxine sodium share the same indications as Thyquidity.
- Thyquidity carries a boxed warning stating that it is not for treatment of obesity or for weight loss.
- Thyquidity is contraindicated in patients with uncorrected adrenal insufficiency.
- Warnings and precautions for Thyquidity include cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease; myxedema coma; acute adrenal crisis in patients with concomitant adrenal insufficiency; prevention of hyperthyroidism or incomplete treatment of hypothyroidism; worsening of diabetic control; and decreased bone mineral density associated with thyroid hormone over replacement.
- Adverse reactions associated with Thyquidity therapy are primarily those of hyperthyroidism due to therapeutic overdose: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash.
- Thyquidity should be administered as a single daily oral dose, on an empty stomach, one-half to one hour before breakfast. The dose of Thyquidity for hypothyroidism or pituitary thyroid-stimulating hormone (TSH) suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated.
 - Refer to the Thyquidity drug label for additional dosing and administration recommendations.

- Regulance/Vertice Specialty Group's launch plans for Thyquidity are pending. Thyquidity will be available as a 100 mcg/5 mL oral solution (in 100 mL bottles).



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.